Final project plan for pharma JA Regorafenib (Stivarga©)

This is the final project plan of the pharma JA on Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatment.

Project Plan